The registry follows the ESC/EACTS guideline and further investigates the clinical performance and short-term safety of RMS (Resorbable Magnesium Scaffolds) in a real world setting within the scope of its intended use without further (medical related) exclusion criteria according to their respective instructions for use (IFU).
Study Type
OBSERVATIONAL
Enrollment
1,106
MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.
Freesolve is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.
Cairns Hospital
Cairns, Australia
COMPLETEDHeart Center Segeberger Kliniken
Bad Segeberg, Germany
RECRUITINGTarget Lesion Failure (TLF)
The primary endpoint will be Target Lesion Failure (TLF) at 12 months. TLF is a composite of Cardiac Death, Target Vessel Q-wave or non-Q wave MI, or clinically driven Target Lesion Revascularization (TLR).
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Krankenhaus Buchholz
Buchholz, Germany
COMPLETEDKlinikum Westfalen, Knappschaft KH
Dortmund, Germany
COMPLETEDKlinikum Herford
Herford, Germany
COMPLETEDHerz-und Gefäßzentrum Oberallgäu-Kempten
Kempten, Germany
COMPLETEDCentro Cardiologico Monzino
Milan, Lombardy, Italy
RECRUITINGDaugavpils Regional Hospital
Daugavpils, Latvia
COMPLETED1 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ w Lublinie
Lublin, Poland
RECRUITINGSUSCCH Banska Bystrica
Banská Bystrica, Slovakia
COMPLETED...and 3 more locations